SHANGHAI, Dec. 4, 2023 /PRNewswire/ On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company.
Abbisko Therapeutics has entered into a licensing agreement with Merck. Under the agreement, Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib for all indications in Chinese mainland, Hong Kong, Macau and Taiwan, and Abbisko Therapeutics will retain the exclusive rights to develop pimicotinib.
SHANGHAI, Dec. 4, 2023 /PRNewswire/ On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany. Under the terms of the agreement, Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib (ABSK021) for all indications in Chinese.